DUBLIN--(BUSINESS WIRE)--The "Bronchiectasis - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This latest Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.
Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 6 and 2 respectively.
Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Report Coverage
- Bronchiectasis - Overview
- Bronchiectasis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Bronchiectasis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bronchiectasis - Companies Involved in Therapeutics Development
- Bronchiectasis - Drug Profiles
- Bronchiectasis - Dormant Projects
- Bronchiectasis - Discontinued Products
- Bronchiectasis - Product Development Milestones
- Featured News & Press Releases
- Feb 03, 2020: Insmed announces positive top-line results from phase 2 WILLOW study of INS1007 in patients with Non-Cystic Fibrosis Bronchiectasis
- Jun 07, 2019: Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference
- Oct 12, 2017: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions
- May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007
- Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA
- Jan 07, 2014: Alitair Receives Orphan Drug Designation for Erdosteine in Bronchiectasis
- Jun 24, 2013: Kamada Receives Two Key Patents Covering Its New Alpha-1 Antitrypsin Product
- Jun 09, 2009: Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis
- Dec 16, 2008: Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
Companies Mentioned
- Alitair Pharmaceuticals Inc
- Chiesi Farmaceutici SpA
- Helperby Therapeutics Group Ltd
- Insmed Inc
- Kamada Ltd
- Novabiotics Ltd
- OrPro Therapeutics Inc
- Parion Sciences Inc
- Polyphor AG
- Recipharm AB
- Santhera Pharmaceuticals Holding AG
- Savara Inc
- Therapeutic Systems Research Laboratories Inc
- Zambon Co SpA
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/do5x76
